Bioregulators · Dosing reference

Thymagen dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: Intranasal or injection (varies by study)
Frequency: Not established
Half-life: Not established
Evidence grade: Not yet assessed
Vial sizes on the market: Not recorded
Other forms seen: —

What Thymagen is

A short thymus-associated bioregulator peptide studied in laboratory research on immune signaling and cellular regulation.

The mechanistic literature on Glu-Trp is framed around immune and haematopoietic regulation rather than a defined receptor. A 1991 Russian-language study in guinea pigs reported that thymus-derived immunocorrectors, thymagen among them, altered cyclic nucleotide catabolism in spleen lymphocytes, with sensitisation associated with a fall in the cAMP/cGMP ratio and the peptides associated with increased activity of… How it works →

Key evidence

Khudzik et al., Problemy Tuberkuleza (in Russian) · 1998 · Humans (553 patients with destructive pulmonary tuberculosis)
The authors reported a favourable outcome attributed to immunocorrector treatment early in combined therapy, and the most favourable result in the thymogen-plus-interferon group. Available to this review only as an English abstract of a Russian-language paper; no control group without immunocorrector is described. ⁵
Deigin et al., International Immunopharmacology · 2020 · Animals and ex-vivo bone marrow (mice; intact bone marrow progenitors)
States that Glu-Trp was separated from thymus homogenate and developed into the immunostimulating preparation Thymogen, and reports that the D-enantiomer dipeptides inhibit proliferation of haematopoietic progenitors — the opposite direction of effect from the L-peptide. ²
Deigin et al., ChemMedChem · 2016 · Animals and ex-vivo bone marrow (intact mice; irradiated bone marrow cells)
Three of five synthesised analogues were reported to show haemostimulatory activity in vivo in intact mice and ex vivo in irradiated bone marrow cells. ³

All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered Thymagen. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

In the preoperative study, intranasal Thymogen was given for 7 days before surgery ^12.

Cycle-length evidence for Thymagen

Who was excluded from the studies

The preoperative trial enrolled only elderly surgical patients with abdominal or retroperitoneal solid tumors ^12.

Thymagen draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

Handling should follow the certificate of analysis and written documentation supplied with the specific lot; no stability or handling data specific to this compound were identified in the sources reviewed. Short lyophilised peptides are generally treated as hygroscopic, light-sensitive solids whose reconstituted solutions are chemically less stable than the dry material. Amiravo does not provide preparation, reconstitution or administration instructions.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API ^9. Secondary and primary sources describe Thymogen as having been developed into a marketed preparation in Russia ^2, but Amiravo could not verify any national marketing authorisation from a primary regulatory source.
United States (FDA): There is no approved FDA application for this peptide; an openFDA Drug Label API query returned no matching human drug labeling ^9. Neither "thymagen" nor "thymogen" appears in any of the three categories of FDA's list of bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, as updated 14 May 2026 ^10.
Sport (WADA): Not named in the WADA 2026 Prohibited List under either spelling ^11. That absence is hedged negative evidence, not a clearance. Section S0 prohibits at all times "any pharmacological substance which is not currently approved by any governmental regulatory health authority for human therapeutic use" and notes that the class "covers many different substances including but not limited to" its named examples, so whether this dipeptide falls under S0 depends on a regulatory-approval question Amiravo could not resolve from a primary source; section S2 additionally prohibits listed peptide hormones and growth factors "and other substances with similar chemical structure or similar biological effect(s)" ^11.

Status varies by country and changes over time. How we describe regulatory status.

Thymagen compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Thymagen	Not approved — research use only	—	None established	—
Thymalin	Not approved — research use only	B	None established	—
Cortagen	Not approved — research use only	C	None established	—
Pinealon	Not approved — research use only	C	None established	—
Testagen	Not approved — research use only	D	None established	—
Vesugen	Not approved — research use only	C	None established	—

Frequently asked questions

What doses of Thymagen have been studied in humans?

None that establish an amount. Thymagen is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.

Is there an established Thymagen cycle length?

No cycle length or break has been established. Human studies administered Thymagen for the periods listed on this page; those are study durations, not a recommended course.

How much bacteriostatic water should be added to a Thymagen vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

Is Thymagen FDA-approved?

Not approved — research use only. Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API ^9. Secondary and primary sources describe Thymogen as having been developed into a marketed preparation in Russia ^2, but Amiravo could not verify any national marketing authorisation from a primary regulatory source.

References

Effect of thymagen, thymalin and vilosen on the cAMP and cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization and anaphylactic shock (in Russian) Ukrainskii Biokhimicheskii Zhurnal. 1991
Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides International Immunopharmacology. 2020
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity ChemMedChem. 2016
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line International Journal of Molecular Sciences. 2022
Immunotherapy of pulmonary tuberculosis (in Russian) Problemy Tuberkuleza. 1998
PubMed query for "thymagen" (1 record, a 1991 Russian-language paper that uses the spellings thymagen and thymogen for the same agent) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
PubMed query for "thymogen" (103 records under the NLM supplementary concept “thymogen”) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
ClinicalTrials.gov registry query for "thymagen" (0 studies returned) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
openFDA Drug Label API query for "thymagen" (no approved human drug labeling for a peptide of this name) U.S. Food and Drug Administration / openFDA. 2026
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
[Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity] Adv Gerontol. 2011
[Immunomodulating activity of thymogen in acute pancreatitis] Vopr Pitan. 2000
[Thymogen in the complex treatment of inflammatory diseases of the female genital system] Akush Ginekol (Mosk). 1992
[Repair stimulator alpha-glutamyl-tryptophan in the complex therapy of chronic atrophic gastritis: results of histological examination] Arkh Patol. 2023
[Endoscopic and morphometric analysis of the reduction of acute inflammatory process in the gastric mucosa after therapy with Regasthym Gastro] Ter Arkh. 2023
[The effect of thymogen on the state of immunity in destructive pulmonary tuberculosis] Voen Med Zh. 1999

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error